Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

500,000-Patient study aims to unlock secrets of chronic liver disease

NCT ID NCT05744713

Knowledge-focused Sponsor: Target PharmaSolutions, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will follow up to 500,000 adults with chronic liver disease or cirrhosis to understand how the disease progresses and how treatments are used in everyday practice. Researchers will collect data from medical records and patient reports to improve care and outcomes. No new treatments are being tested; instead, the goal is to gather real-world evidence to guide future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide valuable insights into how chronic liver disease progresses and how current treatments work in real-world settings.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may take years and might not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Dec 2037

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include adults who are being managed for chronic liver disease or cirrhosis of any etiology.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Disease Cohort •Adult\* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface Engaged Cohort * Adult\* patients diagnosed and managed for CLD/cirrhosis invited to participate * Ability to provide written informed consent Exclusion Criteria: Disease Cohort * Death * Manual removal (sponsor or site request) * No EHR interface encounter \> 3 years. Engaged Cohort * Patient expressed desire to withdraw consent to complete PROs * Failure to complete PROs within 24 weeks of initial invitation * Greater than 24 months lapse of survey completion after baseline surveys completed * Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic liver disease Cirrhosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atrium Health Center for Liver Disease and Transplant

    Charlotte, North Carolina, 28204, United States

  • Baylor College of Medicine

    Houston, Texas, 77021, United States

  • Baylor Scott & White Research Institute

    Dallas, Texas, 75246, United States

  • Columbia University Irving Medical Center/ New York Presbyterian Hospital

    New York, New York, 10032, United States

  • Georgetown Medstar Transplant Institute

    Washington D.C., District of Columbia, 20007, United States

  • Keck School of Medicine of USC

    Los Angeles, California, 90033, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • Stanford Medicine

    Redwood City, California, 94063, United States

  • Temple University - Lewis Katz School of Medicine

    Philadelphia, Pennsylvania, 19140, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.